2-Arahidonilgliceril etar
| |
| Nazivi | |
|---|---|
| IUPAC nazivs
2-[(5Z,8Z,11Z,14Z)-5,8,11,14- Ikosatetraen-
1-iloksi]-1,3-propanediol | |
| Drugi nazivi
2-AGE, 2-arahidonilgliceril etar, Noladin etar, Noladin
| |
| Identifikacija | |
3D model (Jmol)
|
|
| ChemSpider | |
| |
| Svojstva | |
| C23H40O3 | |
| Molarna masa | 364,56 g/mol |
Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa). | |
 verifikuj (šta je   ?)
| |
| Reference infokutije | |
2-Arahidonilgliceril etar (2-AGE, Noladinski etar) je endokanabinoid. Njegova izolacija iz svinjskog mozga, strukturno određivanje i sinteza su opisani 2001.[3]
Farmakologija
[уреди | уреди извор]2-AGE se vezuje sa Ki od 21 nM za CB1 receptor[3] i 480 nM za CB2 receptor.[4] On je agonist na oba receptora i parcijalni agonist za TRPV1 kanal.[5] Nakon vezivanja CB2 receptora on inhibira adenilat ciklazu i stimuliše ERK-MAPK.[6] U poređenju sa 2-arahidonoilglicerolom, noladin je metabolički stabilniji, te ima duži poluživot.[7] On snižava intraokularni pritisak,[7] povišava stepen GABA preuzimanja u globus pallidus pacova[8] i ima neuroprotektivno dejstvo.[9]
Reference
[уреди | уреди извор]- ^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.
- ^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
- ^ а б Hanus, L.; Abu-Lafi, S.; Fride, E.; Breuer, A.; Vogel, Z.; Shalev, D.; Kustanovich, I.; Mechoulam, R. (2001). „2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor”. Proceedings of the National Academy of Sciences. 98 (7): 3662—3665. PMC 31108
. PMID 11259648. doi:10.1073/pnas.061029898.
- ^ Shoemaker JL, Joseph BK, Ruckle MB, Mayeux PR, Prather PL (2005). „The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors”. J. Pharmacol. Exp. Ther. 314 (2): 868—75. PMID 15901805. doi:10.1124/jpet.105.085282.
- ^ Duncan M, Millns P, Smart D, Wright JE, Kendall DA, Ralevic V (2004). „Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 Gi/o linked receptor”. Br. J. Pharmacol. 142 (3): 509—18. PMC 1574960 . PMID 15148262. doi:10.1038/sj.bjp.0705789.
- ^ Shoemaker JL, Ruckle MB, Mayeux PR, Prather PL (2005). „Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors”. J. Pharmacol. Exp. Ther. 315 (2): 828—38. PMID 16081674. doi:10.1124/jpet.105.089474.
- ^ а б Laine K, Järvinen K, Mechoulam R, Breuer A, Järvinen T (2002). „Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid”. Invest. Ophthalmol. Vis. Sci. 43 (10): 3216—22. PMID 12356827.
- ^ Venderova K, Brown TM, Brotchie JM (2005). „Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus”. Exp. Neurol. 194 (1): 284—7. PMID 15899265. doi:10.1016/j.expneurol.2005.02.012.
- ^ Sun Y; Alexander SP; Garle MJ; et al. (2007). „Cannabinoid activation of PPARα; a novel neuroprotective mechanism”. Br. J. Pharmacol. 152 (5): 734—43. PMC 2190030 . PMID 17906680. doi:10.1038/sj.bjp.0707478.
